Literature DB >> 19635192

[Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway].

Ling Wang1, Li-Hong Liu, Bao-En Shan, Chao Zhang, Mei-Xiang Sang, Jia Li.   

Abstract

BACKGROUND AND
OBJECTIVE: Celecoxib can inhibit cell proliferation, regulate cell cycle and induce apoptosis, but the underlying mechanisms are still unclear. This study was to investigate the association between the NF-kappaB (kappaB) pathway and the apoptosis of breast cancer cell line MDA-MB-231 induced by celecoxib.
METHODS: The expression of cyclo-oxygenase-2 (COX-2) mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR). Cell proliferation and cell cycle were detected by MTT and flow cytometry (FCM), respectively. The protein expressions of caspase-3 and p65 in MDA-MB-231 cells were detected by western blot.
RESULTS: After incubation with different concentrations of celecoxib for 48 h, COX-2 mRNA expression in MDA-MB-231 cells was decreased in a dose-dependent manner compared with untreated cells (P<0.05). Proliferation of MDA-MB-231 cells was reduced drastically in a dose-and time-dependent manner after celecoxib treatment (P<0.05). Combination of prostaglandin E2 (PGE2) and celecoxib exerted similar inhibition effect to celecoxib alone on cell growth (P>0.05). High-dose celecoxib induced an increase in the percentage of G0/G1 phase cells accompanied by the change in DNA ploidy. The cellular caspase-3 level was enhanced whereas the p65 level was decreased in celecoxib-treated MDA-MB-231 cells after 24 h in comparison to those in the control cells.
CONCLUSION: Celecoxib could inhibit MDA-MB-231 cell proliferation and promote cell apoptosis by down-regulating the NF-kappaB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635192

Source DB:  PubMed          Journal:  Ai Zheng


  6 in total

1.  Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Authors:  Giuliana Cássia Morrone Taromaru; Vilmar Marques DE Oliveira; Maria Antonieta Longo Galvão Silva; Wagner Ricardo Montor; Fabio Bagnoli; José Francisco Rinaldi; Tsutomu Aoki
Journal:  Oncol Lett       Date:  2011-12-21       Impact factor: 2.967

2.  Celecoxib enhances sensitivity to chemotherapy drugs of T-cell lymphoma.

Authors:  Ming Ma; Xingxiao Yang; Lianmei Zhao; Xuexiao Wang; Lihua Liu; Wenjing Jiao; Yuanyuan Wei; Baoen Shan
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

3.  Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells.

Authors:  Florastina Payton-Stewart; Syreeta L Tilghman; LaKeisha G Williams; Leyte L Winfield
Journal:  Biochem Biophys Res Commun       Date:  2014-07-02       Impact factor: 3.575

4.  Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.

Authors:  Anjana Kumari Negi; Archana Bhatnagar; Navneet Agnihotri
Journal:  Inflammopharmacology       Date:  2016-01-09       Impact factor: 4.473

Review 5.  Celecoxib in breast cancer prevention and therapy.

Authors:  Jieqing Li; Qiongyu Hao; Wei Cao; Jaydutt V Vadgama; Yong Wu
Journal:  Cancer Manag Res       Date:  2018-10-26       Impact factor: 3.989

6.  Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line.

Authors:  Ling Wang; Fubiao Kang; Jie Li; Jing Zhang; Baoen Shan
Journal:  Cancer Cell Int       Date:  2013-02-12       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.